ADAM8 and neoplasm: Furthermore, a panel of highly specific monoclonal antibodies against ADAM8, identified through hybridoma screening, has shown significant anticancer activity in TNBC models, with two lead antibodies, ADP2 and ADP13, reducing tumour growth and metastasis and improving survival in mice [148].